索拉非尼联合X线立体定位放疗治疗肝细胞癌的疗效评价  

The therapeutic efficacy evaluation of sorafenib combined with cyberknife in primary liver cancer

作　　者：汪昉睿[1] 钱建民[1] 王恩敏[1] 王乾伟[1] 马震宇[1] 

机构地区：[1]复旦大学附属华山医院外科肝脏外科中心,上海200040

出　　处：《腹部外科》2013年第2期86-89,共4页Journal of Abdominal Surgery

摘　　要：目的探讨靶向药物索拉非尼联合射波刀在临床治疗无法手术切除的肝细胞癌患者中的安全性及初步疗效。方法回顾性分析自2009年1月至2011年2月间诊断为肝细胞癌、无法接受手术根治性治疗而接受索拉非尼联合射波刀的10例患者的相关临床数据。结果本研究中共10例患者入组，生存时间为（15．5±5．38）个月，中位疾病进展时间7个月。随访至2011年8月，根据BCLC分期，B级患者的生存时间为（16．67±6．56）个月，C级患者的生存时间为（13．75±2．87）个月（P=0．433）。治疗前肿瘤总直径为（6．96±2．75）cm，治疗后6个月为（6．55±3．04）cm；治疗前AFP值（933．8±1333．72）μg／L，治疗后为（119．2±182．76）μg／L，（P=0．082），5例患者AFP水平较治疗前下降超过50％。结论索拉非尼联合射波刀治疗可延长无法手术切除的肝细胞癌患者的总生存期，能有效抑制局部肿瘤生长，同时联合治疗的耐受性良好。Objective To evaluate the safety and initial therapeutic efficacy of sorafenib combined with cyherknife in primary liver cancer. Methods From January 2009 to February 2011, 10 patients were diagnosed primary liver cancer. They underwent sorafenib combined cyberknife therapy due to difficulty of resection completely. Their clinical data were retrospectively analyzed. Results The average survival time in patient in this study was （15. 5 ± 5.38） months. Median progression time was 7 months. Patients were followed up to August 2011. Referring to the BCLC grade standard, the average survival time in grade B group was （16. 67 ± 6. 56） months, while in grade C group the average survival time of was （13. 75 ± 2. 87） months. No difference was found between two groups （P = 0. 433）. Before therapy, average diameter of tumor tissue was （6. 96 ± 2. 75） cm and AFP was （933. 8 ± 1 333. 72）μg/L, and after 6 months of therapy, they were respectively （6. 55 ± 3. 04） cm and （119. 2 ± 182. 76） μg/L. The AFP level was declined up to 50% in 5 patients. Conclusion The sorafenib combined with cyberknife therapy may prolong survival time in patient with primary liver cancer with resection difficulty and control tumor tissue growth. The combined therapy brings better tolerance in contrast to the simple surgical procedure.

关 键 词：癌 肝细胞 X线疗法 索拉非尼 

分 类 号：R735.7[医药卫生—肿瘤]